News

January 13, 2020January 13, 2020

Chinook Acquires Global Rights to Develop Atrasentan for Alport, Other Kidney Diseases

News

Chinook Therapeutics acquired the global rights for the development and commercialization of AbbVie‘s atrasentan, an investigational compound for the treatment of people with primary glomerular kidney disease, including patients ... Read more

January 6, 2020January 6, 2020

Gene Therapy Repairs Mutations in Kidney Cells from Alport Patients, Study Shows

News

Tailored gene therapy repaired two mutations associated with Alport syndrome in specialized kidney cells from Alport patients, a preclinical study found. The findings point to patient-specific gene therapy as a ... Read more

December 16, 2019December 16, 2019

US Kidney Disease Data Points to Need for Early Detection and Better Awareness, AKF Says

News

While the latest information from the United States Renal Data System (USRDS) is encouraging, it also highlights the need for early care and heightened awareness of kidney disorders such as ... Read more

December 9, 2019December 18, 2019

Reata and Invitae Partner to Offer Genetic Testing and Counseling for Chronic Kidney Disease

News

To promote the diagnosis of chronic kidney disease (CKD), genetic information company Invitae and Reata Pharmaceuticals are collaborating to offer free testing and counseling support. Alport syndrome accounts for ... Read more

December 5, 2019December 5, 2019

HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases

News

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s ... Read more

December 2, 2019December 2, 2019

NY Kidney Recipient Becomes Spokesman for Alport Syndrome Foundation

News

Until he was diagnosed at age 26, Kevin Schnurr had no idea what Alport syndrome was. And even though the worst is now behind him — thanks to a ... Read more

November 25, 2019November 25, 2019

Sangamo to Launch First-in-human Clinical Trial Testing TX200 Cell Therapy in End-stage Renal Disease

News

The United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has authorized the first-in-human clinical trial testing Sangamo Therapeutics’ TX200, a cell-based CAR-Treg therapy, in preventing rejection of transplanted kidneys in ... Read more

November 18, 2019November 18, 2019

New COL4A4 Mutation Discovered in Young Boy With Alport Syndrome, Case Report Shows

News

Researchers have discovered a new mutation in the COL4A4 gene that leads to the development of Alport syndrome, according to a recent case report. The case report, titled “Autosomal ... Read more

November 13, 2019

Rare Disease Film Festival Highlights Patient and Researcher Unity

News

Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. ... Read more

November 13, 2019November 13, 2019

Bardoxolone May Improve Kidney Function in Alport Patients, Phase 3 Results Suggest

News

Reata Pharmaceuticals’ investigational therapy bardoxolone methyl may effectively improve and preserve renal function in patients with chronic kidney disease caused by Alport syndrome, topline results from a Phase 3 ... Read more

Pin It on Pinterest